CUSIP: 09077J107
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
128,974,508
-
Share change
-
-29,793,142
-
Total reported value
-
$36,136,400
-
Put/Call ratio
-
0%
-
Price per share
-
$0.28
-
Number of holders
-
77
-
Value change
-
-$5,624,109
-
Number of buys
-
38
-
Number of sells
-
26
Quarterly Holders Quick Answers
What is CUSIP 09077J107?
CUSIP 09077J107 identifies BRDS - BRIDGEBIO PHARMA INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 09077J107:
Institutional Holders of BRIDGEBIO PHARMA INC - COM (BRDS) as of Q1 2023
As of 31 Mar 2023,
BRIDGEBIO PHARMA INC - COM (BRDS) was held by
77 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
128,974,508 shares.
The largest 10 holders included
FMR LLC, Valor Management LLC, SC US (TTGP), LTD., G.F.W. Energy XII, L.P., VANGUARD GROUP INC, BlackRock Inc., Accel Growth Fund IV Associates L.L.C., Upfront Ventures Management, LLC, CAISSE DE DEPOT ET PLACEMENT DU QUEBEC, and Zuckerman Investment Group, LLC.
This page lists
77
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.